Ionis Pharmaceuticals, Inc.
Compositions for modulating expression of C9ORF72 antisense transcript
Last updated:
Abstract:
Disclosed herein are compositions and methods for reducing expression of C9ORF72 antisense transcript in an animal with C9ORF72 antisense transcript specific inhibitors. Such methods are useful to treat, prevent, or ameliorate neurodegenerative diseases in an individual in need thereof. Such C9ORF72 antisense transcript specific inhibitors include antisense compounds.
Status:
Grant
Type:
Utility
Filling date:
28 Aug 2019
Issue date:
7 Dec 2021